The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions. (GeNeo2)
2026년 7월 16일 업데이트: The Belgian Society of Medical Oncology
The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions: The Belgian PRECISION Study of the BSMO in Collaboration With the Cancer Center of Sciensano.
A total of 550 patients with metastatic solid tumors or primary CNS malignancy will be recruited on a first come first serve basis at one of the 14 participating centers : UZL, UZG, Imelda, ZAZ, AZ Klina, CHU Liège, GHdC, CHU UCL Namur, IJB, UZB, CUSL, UZA, VITAZ and Jessa Zh..
> 500 patients with tissue available will undergo CGP centrally at UZ Leuven (Roche AVENIO Tumor Tissue CGP kits, Novaseq platform).
> 50 patients without tissue available will undergo liquid biopsy testing at Foundation Medicine (FoundationOne Liquid CDx).
The sequencing data generated by UZ Leuven laboratory will then be further analysed (secondary and tertiary analysis) by one of the eight laboratories participating in the study: UZL, UZG, IJB, CUSL, IPG, UZA, Jessa zh. and CHU Liège.
연구 개요
상태
상태
모병
정황
정황
개입 / 치료
개입 / 치료
상세 설명
GeNeo 2.0 Study PRIMARY OBJECTIVE AND ENDPOINTS
To describe the genomic landscape of advanced solid tumors and primary CNS cancer as evaluated by CGP of tumor or ctDNA (for all included patients and tumor types separate). To do so, following calculations will be performed :
- Prevalence of ESCAT level 1, 2, 3 or 4 alterations based on MTB discussion of Roche AVENIO Tumor Tissue CGP kit results.
- Prevalence of ESCAT level 1, 2, 3 or 4 alterations based on MTB discussion of Foundation One Liquid CDx results.
- Prevalence of genomic alterations according to altered gene, type of variant of tumor type.
GeNeo 2.0 Study SECONDARY OBJECTIVES AND ENDPOINTS
- To describe the number of patients receiving a treatment recommendation by the MTB.
- To describe the uptake of the MTB recommendations.
- To evaluate the treatment recommendations proposed by the MTB.
- To evaluate the reasons for discordance between the actual treatment and MTB recommendation.
- To evaluate the turnaround time of tumor CGP and ctDNA testing.
- To evaluate the technical success rate of tumor CGP and ctDNA testing.
- To evaluate the impact of CGP on patient referral and trial inclusion.
All secondary analyses will be performed for all included patients, for tumor/ctDNA CGP testing and for tumor types separate. To do so, following calculations will be performed :
- Proportion of patients receiving at least 1 MTB recommendation
- Proportion of patients with at least 1 MTB recommendation that initiated the recommended treatment.
- Qualitative and quantitative descriptive analysis of treatment recommendations proposed by the MTB.
- Descriptive analysis of reasons for discordance between actual treatment and MTB recommendations.
- Proportion of patients with a time between sample pick-up and MTB report ≤28 days.
- Proportion of patients in which tumor CGP and ctDNA testing failed for technical reasons + descriptive analysis of potential reasons.
- Descriptive analysis of patient referrals between centers for participation in genotype-driven clinical trials.
연구 유형
연구 유형
관찰
등록 (추정된)
등록
550
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
연구 연락처
- 이름: Julie Maetens
- 전화번호: +32 2 642 54 90
- 이메일: Julie.Maetens@sciensano.be
연구 연락처 백업
- 이름: Gordana RaicevicToungouz
- 전화번호: +32 2 642 54 90
- 이메일: Gordana.RaicevicToungouz@sciensano.be
연구 장소
-
-
-
Anderlecht, 벨기에, 1070
- 모병
- Institute Jules Bordet
-
연락하다:
- Sophie Vankerckhove, Study Coordinator
- 전화번호: +32 2 541 73 41
- 이메일: sophie.vankerckhove@hubruxelles.be
-
수석 연구원:
- Philippe Aftimos, Oncologist
-
Antwerp, 벨기에, 2030
- 모병
- ZAS
-
연락하다:
- Abdelbari Baitar, Study Coordinator
- 전화번호: +32 3 443 37 59
- 이메일: Abdelbari.Baitar@zas.be
-
수석 연구원:
- Kevin Punie, Oncologist
-
Bonheiden, 벨기에, 2820
- 모병
- Imelda
-
연락하다:
- Ann Pauwels, Study Coordinator
- 전화번호: +32 1 550 46 25
- 이메일: sec.oncologie@imelda.be
-
수석 연구원:
- Heidi Van den Bulck, Oncologist
-
Brasschaat, 벨기에, 2930
- 모병
- AZ Klina
-
연락하다:
- Sofie Herman, Study Coordinator
- 전화번호: +32 3 650 52 77
- 이메일: Sofie.Herman@klina.be
-
수석 연구원:
- Wim Demey, Oncologist
-
Edegem, 벨기에, 2650
- 모병
- Universitaire Ziekenhuis Antwerpen
-
연락하다:
- Greet De Craen, Study Coordinator
- 전화번호: +32 3 821 41 21
- 이메일: Onco.logi@uza.be
-
수석 연구원:
- Hans Prenen, Oncologist
-
Ghent, 벨기에, 9000
- 모병
- UZ Gent
-
연락하다:
- Ellen De Bruycker, Study Coordinator
- 전화번호: +32 9 332 15 92
- 이메일: Ellen.debruycker@uzgent.be
-
수석 연구원:
- Eline Naert, Oncologist
-
Gilly, 벨기에, 6060
- 모병
- GHdC
-
연락하다:
- Matthias Papier, Study Coordinator
- 전화번호: +32 6 011 06 09
- 이메일: matthias.papier@ghdc.be
-
수석 연구원:
- David Schröder, Oncologist
-
Hasselt, 벨기에, 3500
- 모병
- Jessa Ziekenhuis
-
연락하다:
- Astrid Winnepenninckx, Study Coordinator
- 전화번호: +32 11 33 79 92
- 이메일: astrid.winnepenninckx@jessazh.be
-
연락하다:
- Hanne Oosterbos, Study Coordinator
- 이메일: Hanne.Oosterbos@jessazh.be
-
수석 연구원:
- Jeroen Mebis, Oncologist
-
Jette, 벨기에, 1090
- 모병
- UZ Brussel
-
연락하다:
- Vanessa Fastenaekels, Study Coordinator
- 전화번호: +32 2 474 9478
- 이메일: Vanessa.Fastenaekels@uzbrussel.be
-
수석 연구원:
- Sofie Joris, Oncologist
-
Leuven, 벨기에, 3000
- 모병
- UZ Leuven
-
연락하다:
- Anne Baggerman, Study Coordinator
- 전화번호: +32 16 34 66 78
- 이메일: Anne.Baggerman@uzleuven.be
-
수석 연구원:
- Sabine Tejpar, Oncologist
-
Liège, 벨기에, 4000
- 모병
- CHU Liège Sart Tilman
-
연락하다:
- Hélène Schroeder, Study Coordinator
- 전화번호: +32 4 323 40 74
- 이메일: hschroeder@chuliege.be
-
수석 연구원:
- Christine Gennigens, Oncologist
-
Namur, 벨기에, 5000
- 모병
- CHU UCL Namur
-
연락하다:
- Sylvie Ledroit, Study Coordinator
- 전화번호: +32 8 170 28 24
- 이메일: Sylvie.Ledroit@chuuclnamur.uclouvain.be
-
수석 연구원:
- Donatienne Taylor, Oncologist
-
Sint-Niklaas, 벨기에, 9100
- 모병
- Vitaz
-
연락하다:
- Jenas Stevenheydens, Study Coordinator
- 전화번호: +32 3 760 76 24
- 이메일: Jenas.Stevenheydens@vitaz.be
-
수석 연구원:
- Willem Lybaert, Oncologist
-
Woluwe-Saint-Lambert, 벨기에, 1200
- 모병
- Les Cliniques Universitaires St Luc
-
연락하다:
- Anaïs Thomas, Study Coordinator
- 전화번호: + 32 2 764 81 28
- 이메일: anais.thomas@saintluc.uclouvain.be
-
수석 연구원:
- Cédric Van Marcke, Oncologist
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
샘플링 방법
확률 샘플
연구 인구
550 consecutive patients with metastatic solid tumors that are eligible for a systemic therapy recruited on a first come first serve basis.
500 patients will be tested on a tissue biopsy and 50 patients will be tested on a liquid biopsy when tissue biopsy is not available or feasible for safety reason.
설명
Inclusion Criteria:
- Adult patient (minimum 18 years) able to provide written informed consent for GeNeo 2.0.
- ECOG Performance status ≤2
- Patients with advanced solid tumors or primary CNS tumors that are candidates for systemic anticancer therapy and open for enrollment in a potential downstream therapeutic trial. Enrollment in early treatment lines is strongly encouraged Tumor cohorts of breast cancer and lung cancer will be prioritized, with a minimum cap of 100 for each tumor type. Recruitment for all other tumor type cohorts will be capped at a maximum of 40 patients per tumor type. The MTB can decide on prematurely closing or extending tumor type cohorts based on treatment recommendations, clinical trial landscape or downstream treatment options. Enrollment of patients early in the advanced treatment setting will be strongly encouraged.
- Patients should have archived tissue available from a metastatic (preferred) or primary lesion biopsy for comprehensive profiling. The tissue should not be more than 2 years-old and fixed in 10% neutral buffered formalin. Tumor cell content should be >20%
Exclusion Criteria:
- Life expectancy of ≤12 weeks according to the local investigator
- Clinically significant hematopoietic, renal and/or hepatic dysfunction, according to the local investigator, which would make them ineligible for MGTO therapy
- Patients unwilling to comply with GeNeo 2.0 protocol data collection, data sharing and other study procedures
- Patients unwilling to provide informed consent and comply with study procedures.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
그룹/코호트 수
1
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Agnostic cohort
Tumor cohorts of breast cancer and lung cancer will be prioritized, with a minimum cap of 100 for each tumor type.
Recruitment for all other tumor type cohorts will be capped at a maximum of 40 patients per tumor type.
The MTB can decide on prematurely closing or extending tumor type cohorts based on treatment recommendations, clinical trial landscape or downstream treatment options.
Enrollment of patients early in the advanced treatment setting will be strongly encouraged.
|
To determine the Added Value of Tissue and Liquid Biopsy NGS profiling in Advanced Solid Tumor Treatment Decisions: The Belgian PRECISION study of the BSMO in collaboration with the Cancer Center of Sciensano (GeNeo 2.0)
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Distribution of ESCAT Actionability Levels Identified by Comprehensive Genomic Profiling
기간: Through study completion, an average of 1 year.
|
Participants with at least one molecular tumor board recommendation were classified according to the highest ESCAT level identified following comprehensive genomic profiling.
ESCAT Level I represents alterations with established clinical utility whereas Levels II-IV represent progressively lower levels of clinical evidence.
The reported results will count the number of participants for each ESCAT level group.
|
Through study completion, an average of 1 year.
|
|
Distribution of Genomic Alteration Types Identified by Comprehensive Genomic Profiling
기간: Through study completion, an average of 1 year.
|
The reported values represent the prevalence of genomic alterations according to altered gene, type of variant of tumor type.
|
Through study completion, an average of 1 year.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of patients receiving a treatment recommendation
기간: Through study completion, an average of 1 year.
|
The reported results will count the number and percentage of participants for whom at least one treatment recommendation was issued by the Molecular Tumor Board following comprehensive genomic profiling.
|
Through study completion, an average of 1 year.
|
|
% of uptake of the MTB recommendations
기간: Through study completion, an average of 1 year.
|
The reported results will measure the % of patients, with at least 1 MTB recommendation, who initiated the recommended treatment.
|
Through study completion, an average of 1 year.
|
|
Treatment recommendations quality.
기간: Through study completion, an average of 1 year.
|
The reported results will show a qualitative and quantitative descriptive analysis of treatment recommendations proposed by the MTB.
|
Through study completion, an average of 1 year.
|
|
Participants whose treatment differed from the Molecular Tumor Board recommendation
기간: Through study completion, an average of 1 year.
|
The reported results will show a descriptive analysis of reasons for discordance between actual treatment and MTB recommendations.
|
Through study completion, an average of 1 year.
|
|
Participants with turnaround time within 28 days
기간: Through study completion, an average of 1 year.
|
The reported results will count the number and percentage of participants for whom the interval between sample receipt and Molecular Tumor Board recommendation did not exceed 28 days (14 days for testing and 14 days for MTB review).
|
Through study completion, an average of 1 year.
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
수사관
- 연구 의자: Philippe Aftimos, Oncologist, Jules Bordet Institute
- 연구 의자: Kevin Punie, Oncologist, ZAS
- 연구 의자: Jacques de Grève, Oncologist, Universitair Ziekenhuis Brussel
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
연구 시작
2025년 10월 22일
기본 완료 (추정된)
기본 완료
2027년 5월 1일
연구 완료 (추정된)
연구 완료
2029년 4월 1일
연구 등록 날짜
최초 제출
최초 제출
2025년 12월 19일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 7월 16일
처음 게시됨 (실제)
처음 게시됨
2026년 7월 20일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 7월 20일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 16일
마지막으로 확인됨
마지막으로 확인됨
2026년 1월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- BSMO 2024-1
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .